For US Healthcare Professionals US Prescribing Information Medication Guide CHOOSE INDICATIONDrugDrug name X NVAF: Reducing stroke risk Chronic CAD/PAD: Reducing the risk of major CV events DVT/PE: Treatment DVT Prophylaxis: After hip/knee replacement surgery Home Clinical Trial COMPASS patient population COMPASS study design Efficacy Profile Chronic CAD/PAD additional outcomes Chronic CAD/PAD major CV events Safety Profile Chronic CAD/PAD safety profile Chronic PAD subgroup safety profile Dosing Home Extensive Evidence Efficacy Profile ITT population Safety, as-treated population Real-world evidence: Stroke risk reduction Safety Profile Safety profile Real-world evidence: Major bleeding Real-world evidence: GI bleeding Real-world evidence: ICH bleeding Real-world evidence: Fatal bleeding Dosing Dose information Renal information Home Extensive Evidence Efficacy Profile Initial treatment Reduction in the risk of recurrence Real-world outcomes Safety Profile Principal safety outcome in initial treatment Major bleeding in initial treatment Safety outcome in recurrence risk reduction Real-world outcomes Dosing Dose information Starter Pack Home Extensive Evidence Efficacy Profile After hip replacement surgery After knee replacement surgery Real-world outcomes Safety Profile After hip replacement surgery After knee replacement surgery Real-world outcomes Dosing DOSING SWITCH AND MANAGEMENT Switching to/from XARELTO® Bleed management considerations Temporary discontinuation Other administration options ACCESS AND SUPPORT Formulary finder Janssen CarePath Program Janssen Prescription Assistance RESOURCES Reprints Patient resources Professional resources Other resources FAQs SEARCH XARELTO® DOSING: ALL INDICATIONS Search Important Safety Information US Prescribing Information Medication Guide For Non-US Visitors Patient Site Change Indication Choose Indication NVAF: Reducing stroke risk Extensive evidence Efficacy profile Safety profile Dosing Chronic CAD/PAD: Reducing the risk of major cardiovascular events Clinical Trial Efficacy profile Safety profile Dosing DVT/PE: Treatment Extensive evidence Efficacy profile Safety profile Dosing DVT Prophylaxis: After hip/knee replacement surgery Extensive evidence Efficacy profile Safety profile Dosing Home Clinical Trial COMPASS patient population COMPASS study design Efficacy Profile Chronic CAD/PAD additional outcomes Chronic CAD/PAD major CV events Safety Profile Chronic CAD/PAD safety profile Chronic PAD subgroup safety profile Dosing Home Extensive Evidence Efficacy Profile ITT population Safety, as-treated population Real-world evidence: Stroke risk reduction Safety Profile Safety profile Real-world evidence: Major bleeding Real-world evidence: GI bleeding Real-world evidence: ICH bleeding Real-world evidence: Fatal bleeding Dosing Dose information Renal information Home Extensive Evidence Efficacy Profile Initial treatment Reduction in the risk of recurrence Real-world outcomes Safety Profile Principal safety outcome in initial treatment Major bleeding in initial treatment Safety outcome in recurrence risk reduction Real-world outcomes Dosing Dose information Starter Pack Home Extensive Evidence Efficacy Profile After hip replacement surgery After knee replacement surgery Real-world outcomes Safety Profile After hip replacement surgery After knee replacement surgery Real-world outcomes Dosing DOSING SWITCH AND MANAGEMENT Switching to/from XARELTO® Bleed management considerations Temporary discontinuation Other administration options ACCESS AND SUPPORT Formulary finder Janssen CarePath Program Janssen Prescription Assistance RESOURCES Reprints Patient resources Professional resources Other resources FAQs SEARCH XARELTO® DOSING: ALL INDICATIONS
NVAF: Reducing stroke risk Extensive evidence Efficacy profile Safety profile Dosing Chronic CAD/PAD: Reducing the risk of major cardiovascular events Clinical Trial Efficacy profile Safety profile Dosing DVT/PE: Treatment Extensive evidence Efficacy profile Safety profile Dosing DVT Prophylaxis: After hip/knee replacement surgery Extensive evidence Efficacy profile Safety profile Dosing
NVAF: Reducing stroke risk NVAFReducing stroke risk Home Extensive evidence Efficacy profile Safety profile Dosing Chronic: CAD/PAD Reducing the risk of major cardiovascular events Chronic: CAD/PADReducing the risk of major CV events Home Clinical Trial Efficacy profile Safety profile Dosing DVT/PE: Treatment DVT/PETreatment Home Extensive evidence Efficacy profile Safety profile Dosing DVT Prophylaxis: After hip/knee replacement surgery DVT ProphylaxisAfter hip/knee replacement surgery Home Extensive evidence Efficacy profile Safety profile Dosing XARELTO® Dosing: All Indications SWITCH AND MANAGEMENT Switching To/From XARELTO® Bleed Management Considerations Temporary Discontinuation Other Administration Options The DOAC with the most FDA-approved indications for the most thrombotic conditions CV = cardiovascular; DOAC = direct oral anticoagulant; DVT = deep vein thrombosis; NVAF = nonvalvular atrial fibrillation; PE = pulmonary embolism. DVT = deep vein thrombosis; NVAF = nonvalvular atrial fibrillation; PE = pulmonary embolism.
